Abstract
Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.
Original language | English |
---|---|
Journal | Acta Oncologica |
Volume | 57 |
Issue number | 8 |
Pages (from-to) | 1127-1128 |
Number of pages | 2 |
ISSN | 0284-186X |
DOIs | |
Publication status | Published - 3 Aug 2018 |